secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001764013-25-000136
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Immunovant reports ~80% response and 50% ATD-free remission in Graves' disease trial at six months off-treatment
--------------------------------------------------------------------------------

- 80% (17/21) of uncontrolled Graves' patients maintained normal thyroid function six months after stopping batoclimab.
- 50% (8/17) of responders achieved anti-thyroid drug-free remission at six months off-treatment.
- Two registrational trials for lead compound IMVT-1402 in Graves' disease are enrolling with topline data expected in 2027.
- Immunovant will host an investor call on September 3, 2025, at 4:30 p.m. EDT to discuss the data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000136/0001764013-25-000136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000136/imvt-20250903.htm
  HTML page:      https://secwatch.observer/filing/0001764013-25-000136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer